Organon & Co. (NYSE:OGN) Reaches New 52-Week High – What’s Next?

Organon & Co. (NYSE:OGN) shares reached a new 52-week high during trading on Thursday . The stock traded as high as $13.49 and last traded at $13.4850, with a volume of 68157 shares changing hands. The stock had previously closed at $13.48.

Analyst Ratings Changes

Several brokerages have recently issued reports on OGN. Zacks Research raised Organon & Co. from a “strong sell” rating to a “hold” rating in a report on Tuesday, April 14th. BNP Paribas Exane reissued a “neutral” rating and set a $14.00 price target (up from $12.00) on shares of Organon & Co. in a research note on Wednesday, April 29th. Weiss Ratings upgraded Organon & Co. from a “sell (d+)” rating to a “hold (c-)” rating in a report on Friday, May 15th. Finally, Piper Sandler raised Organon & Co. from an “underweight” rating to a “neutral” rating and lifted their price objective for the stock from $5.00 to $14.00 in a research note on Tuesday, April 28th. Five investment analysts have rated the stock with a Hold rating and two have given a Sell rating to the company. According to MarketBeat.com, Organon & Co. has a consensus rating of “Reduce” and a consensus target price of $11.40.

Organon & Co. Stock Down 0.0%

The firm has a market capitalization of $3.54 billion, a PE ratio of 14.49, a PEG ratio of 1.24 and a beta of 1.55. The business’s 50 day simple moving average is $12.66 and its 200 day simple moving average is $9.23. The company has a current ratio of 1.97, a quick ratio of 1.42 and a debt-to-equity ratio of 9.47.

Organon & Co. (NYSE:OGN) last posted its earnings results on Thursday, April 30th. The company reported $0.71 earnings per share for the quarter, missing analysts’ consensus estimates of $0.83 by ($0.12). Organon & Co. had a return on equity of 99.95% and a net margin of 3.99%.The business had revenue of $1.46 billion during the quarter, compared to the consensus estimate of $1.49 billion. During the same quarter last year, the firm earned $1.02 earnings per share. The business’s quarterly revenue was down 3.5% on a year-over-year basis. On average, equities research analysts forecast that Organon & Co. will post 3.23 earnings per share for the current year.

Organon & Co. Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Thursday, June 11th. Shareholders of record on Monday, May 11th were given a dividend of $0.02 per share. The ex-dividend date was Monday, May 11th. This represents a $0.08 dividend on an annualized basis and a yield of 0.6%. Organon & Co.’s dividend payout ratio is 8.60%.

Insider Activity

In related news, SVP Lynette Holzbaur acquired 26,448 shares of the stock in a transaction dated Wednesday, May 6th. The stock was acquired at an average cost of $13.35 per share, with a total value of $353,080.80. Following the purchase, the senior vice president directly owned 52,851 shares of the company’s stock, valued at approximately $705,560.85. This trade represents a 100.17% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. 1.62% of the stock is owned by insiders.

Institutional Investors Weigh In On Organon & Co.

Institutional investors have recently made changes to their positions in the company. Private Management Group Inc. lifted its stake in Organon & Co. by 38.3% in the fourth quarter. Private Management Group Inc. now owns 4,347,073 shares of the company’s stock worth $31,169,000 after purchasing an additional 1,204,979 shares during the last quarter. Gotham Asset Management LLC grew its stake in shares of Organon & Co. by 37.2% during the third quarter. Gotham Asset Management LLC now owns 3,713,204 shares of the company’s stock valued at $39,657,000 after buying an additional 1,007,691 shares during the last quarter. Vanguard Group Inc. grew its stake in shares of Organon & Co. by 11.3% during the third quarter. Vanguard Group Inc. now owns 35,928,403 shares of the company’s stock valued at $383,715,000 after buying an additional 3,650,860 shares during the last quarter. UBS Group AG raised its holdings in shares of Organon & Co. by 55.2% in the fourth quarter. UBS Group AG now owns 4,295,002 shares of the company’s stock worth $30,795,000 after buying an additional 1,527,492 shares during the period. Finally, Kahn Brothers Group Inc. raised its holdings in shares of Organon & Co. by 3.6% in the third quarter. Kahn Brothers Group Inc. now owns 3,616,845 shares of the company’s stock worth $38,628,000 after buying an additional 126,695 shares during the period. Institutional investors own 77.43% of the company’s stock.

About Organon & Co.

Organon & Co is a global healthcare company that was established as an independent, publicly traded entity following its spin-off from Merck & Co in June 2021. Headquartered in Jersey City, New Jersey, Organon focuses on delivering therapeutic solutions across women’s health, biosimilars, and established brands. The company’s creation reflected a strategic effort to concentrate on specialty pharmaceuticals and legacy products with proven patient impact.

In women’s health, Organon provides a broad portfolio of products addressing reproductive and gynecological conditions, including fertility treatments, contraception, and hormone replacement therapies.